TriPath Shareholders OK BD's $350M Acquisition Bid | GenomeWeb
NEW YORK (GenomeWeb News) — TriPath Imaging today said that its shareholders have approved Becton Dickinson’s $350-million bid to acquire the company.
 
The company said it expects the deal to close by tomorrow.
 
In September, BD said it would acquire 93.5 percent of TriPath’s shares for $350 million. TriPath said today that BD has agreed to pay $9.25 a share for the firm’s common stock, which is where the stock was trading this afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.